Navigation Links
KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
Date:4/6/2011

NEW YORK, April 6, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive agreement with AdnaGen, a wholly-owned subsidiary of Alere, Inc., to license specific antibodies. Under the agreement, KellBenx will have exclusive worldwide rights to commercialize the antibodies, which enable the extraction of clinically relevant information from maternal blood through a test that could be widely available as early as 2012.

Fetal Nucleated Red Blood Cells (FNRBCs), which have been identified in maternal blood, can be a source for monitoring and diagnosis of maternal, fetal, and neo-natal health and disease. The KellBenx process involves the enrichment of these FNRBCs with the antibodies licensed from AdnaGen to perform chromosomal or genetic analysis to identify markers of potential disorders. With these antibodies, known as Monoclonal Antibodies with Specificity for Fetal Erythroid Cells, KellBenx will be able to launch clinical trials of its non-invasive test.

"We are delighted to secure a license that allows KellBenx to use the AdnaGen antibodies," said Hassan Bennani, MD., CEO of KellBenx. "This agreement creates the opportunity to begin clinical testing of the exciting laboratory results we have produced over the past year, and it brings us one step closer to bringing a non-invasive prenatal blood test to the market that can detect genetic disorders."

"We're pleased to be able to help KellBenx advance a technology that could have a profound impact on the detection and diagnosis of fetal and neonatal genetic disorders," said Alexander L. Weis, Managing Director of AdnaGen AG. "Our proprietary antibodies will enable the clinical tests that could make this non-invasive testing a reality."

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631-643-2614 or visit kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
2. Core Essence Secures $11.5 Million Series B Financing
3. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
4. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
5. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
6. PLC Systems Secures $4 Million in Financing
7. Biomatrica Secures Strategic Investment from IQT
8. Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
9. TechniScan Secures $10 Million Equity Financing Facility
10. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
11. MedShape Solutions, Inc. Secures Investment From IQT to Support U.S. Intelligence Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):